Literature DB >> 2308203

Risk of seizures and encephalopathy after immunization with the diphtheria-tetanus-pertussis vaccine.

M R Griffin1, W A Ray, E A Mortimer, G M Fenichel, W Schaffner.   

Abstract

We evaluated the risks of seizures and other neurological events following diphtheria-tetanus-pertussis (DTP) immunization for 38,171 Tennessee Medicaid children who received 107,154 DTP immunizations in their first 3 years of life. There were 2 children with encephalitis; both had disease onset more than 2 weeks following DTP immunization. There were 277 children who had febrile seizures, 42 with afebrile seizures, and 37 with seizures associated with other acute neurological illness (acute symptomatic). The risk of febrile seizures in the 0 to 3 days following DTP immunization (n = 6) was 1.5 (95% confidence interval, 0.6 to 3.3) times that of the control period 30 or more days following DTP immunization. There was no evidence that in the 0 to 3 days following DTP immunization the risk of afebrile seizures (n = 1) or acute symptomatic seizures (n = 0) was increased. No child who was previously normal without a prior history of seizures had a seizure in the 0 to 3 days following immunization that marked the onset of either epilepsy or other neurological or developmental abnormality.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2308203

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  11 in total

Review 1.  Above all, do no harm: assessing the risk of an adverse reaction.

Authors:  K Turcotte; P Raina; V A Moyer
Journal:  West J Med       Date:  2001-05

2.  Cellular pertussis vaccine containing a Bordetella pertussis strain that produces a nontoxic pertussis toxin molecule.

Authors:  I Marsili; M Pizza; F Giovannoni; G Volpini; M Bartalini; R Olivieri; R Rappuoli; L Nencioni
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

3.  Vaccination safety update.

Authors:  Burkhard Schneeweiss; Michael Pfleiderer; Brigitte Keller-Stanislawski
Journal:  Dtsch Arztebl Int       Date:  2008-08-25       Impact factor: 5.594

4.  Lessons Learned From Making and Implementing Vaccine Recommendations in the U.S.

Authors:  L Reed Walton; Walter A Orenstein; Larry K Pickering
Journal:  Am J Prev Med       Date:  2015-08-18       Impact factor: 5.043

Review 5.  Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies.

Authors:  Seema Mattoo; James D Cherry
Journal:  Clin Microbiol Rev       Date:  2005-04       Impact factor: 26.132

6.  Statement on pertussis immunization. National Advisory Committee on Immunization.

Authors: 
Journal:  CMAJ       Date:  1993-10-15       Impact factor: 8.262

Review 7.  Acellular pertussis vaccines. Towards an improved safety profile.

Authors:  M E Pichichero
Journal:  Drug Saf       Date:  1996-11       Impact factor: 5.606

Review 8.  No pain no gain? Adjuvant effects of alum and monophosphoryl lipid A in pertussis and HPV vaccines.

Authors:  Thomas C Mitchell; Carolyn R Casella
Journal:  Curr Opin Immunol       Date:  2017-07-17       Impact factor: 7.486

9.  Oral Diazepam in Febrile Seizures Following Acellular Pertussis Vaccination.

Authors:  Mohammadreza Ghazavi; Jafar Nasiri; Omid Yaghini; Rose Soltani
Journal:  Adv Biomed Res       Date:  2019-04-26

10.  Effects of sex and birth weight on non-specific health services use following whole-cell pertussis vaccination: a self-controlled case series analysis.

Authors:  Steven Hawken; Robin Ducharme; Deshayne B Fell; Assaf P Oron; Kumanan Wilson
Journal:  Hum Vaccin Immunother       Date:  2019-04-05       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.